NANOZOLID® TECHNOLOGY PLATFORM
NanoZolid® – a unique proprietary technology
NanoZolid® (NZ) is a safe, flexible and functional method of delivering drugs. When injected, NanoZolid forms a solid depot releasing the active drug over a period of up to six months. As it releases its drug load, the NanoZolid® depot dissolves and is absorbed harmlessly into the body.
NanoZolid® overcomes many of the issues that impact on the effectiveness of treatments and patient quality of life. It reduces the requirements for frequent dosing while retaining the efficacy of the original drug compound with reduced side effects. NanoZolid® reduces patient discomfort, improves compliance and reduces healthcare costs.
NanoZolid® is compatible with molecules from small to larger sizes and can be a drug delivery alternative in most therapy areas where a controlled and sustained release is preferred.
The controlled release of drug compounds can be tailored to the needs of the patient, disease and drugs being used:
The NanoZolid® patented technology uses unique manufacturing steps to provide the controlled and extended release of the drug. The GMP manufacturing process is based on nano-crystallization of hydrating ceramics and isostatic pressure. Partnering with Recipharm, LIDDS has produced drug products (Liproca® Depot) on an industrial scale for clinical use.
A technology with many applications
NanoZolid® has many applications and can be tailored to the needs to the patient, the disease being treated and the drug formulations being used.
The technology’s potential is confirmed in phase II and LIDDS continues to identify future areas of therapy that would benefit from controlled drug release.
In August 2018, the Journal of Drug Delivery Science and Technology published a scientific article entitled “Cold isostatic pressing of hydrating calcium sulfate as a means to produce parenteral slow-release formulations”. The article describes the processes behind the NanoZolid® technology. Link to the article
More than 100 national patents have so far been granted within seven patent families and LIDDS now has comprehensive patent protection for the NanoZolid platform in all major markets.
The patent portfolio is judged to be sound and includes methods for controlling drug release, the manufacturing process, injection devices/aids, the method for controlling the solidification rate and the principle for treating prostate cancer with the NanoZolid technology.
Both the US patent office and the European Patent Office have approved a novel patent for NanoZolid that provides patent protection until 2037 for both the LIDDS technology and for drug formulations based on NanoZolid .
In addition to patent protection, data exclusivity can be granted to LIDDS, applying between 2027 and 2030, which can result in up to 10 years of additional market exclusivity after product registration.
|PATENT||PATENT||US||EU||REST OF THE WORLD|
|1 / 2004||Bioceramic compositions||2027||2024||Not filed|
|2 / 2006||Method to treat prostate cancer||2026||2030||Aus, Can, Chi, Jap, Mex, Russ, S Kor, Nor, Afr, Isr, Ind|
|3 / 2007||Slow local drug release||2027||2029||Aus, Can, Chi, HK, Jap, Mex, Russ, S Kor, Isr, S. Afr, Ind|
|4 / 2009||Mixing tool suspensions||2028||2029||Aus, Can, Chi, Russ, Isr, Jap, Mex, S Korea, Ind, S. Afr|
|5 / 2009||Steering of curing||2029||2029||Aus, Can, Russ, Jap, HK, Mex, S.Kor, Isr, Ind, S. Afr|
|6 / 2016||Manufacturing process||2037||2037||Aus, Can, Chi, HK, Jap, Mex, Russ, S. Kor, Isr, S. Afr, Ind, HK, Br|
|7 / 2020||NanoZolid formulations||2037||2037||Not yet filed|
The Journal of Urology 2017.pdf
Molecular Pharmaceutics 2014.pdf
Journal of Drug Delivery Science and Technology 2018.pdf
European Journal of Pharmaceutics and Biopharmaceutics 2017.pdf
MRI spectroscopy for assessment of intra-prostatic hormone therapy, ISMRM.pdf
Focal drug therapy for localized prostate cancer, EAU.pdf
Local antiandrogen therapy for localized prostate cancer, EAU.pdf
A biopharmaceutical model for prediction of 2-hydroxyflutamide concentrations in plasma and prostate, AAPS.pdf
Anti-tumor effect of 2-hydroxyflutamide as Liproca Depot in the prostate, EAU.pdf